Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age (ACYWX-04)
A Phase 2/3, Randomized, Observer-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine (NmCV-5) and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age
Sponsor: Serum Institute of India Pvt. Ltd.
A PHASE2/PHASE3 clinical study on Vaccine for Meningococcal Disease, this trial is completed. The trial is conducted by Serum Institute of India Pvt. Ltd. and has accumulated 6 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 1 earlier version
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Serum Institute of India Pvt. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .